Ascendis Pharma A/S Announces Pricing of Initial Public Offering
COPENHAGEN, Denmark, Jan. 28, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biopharmaceutical company, today announced the pricing of its initial public offering of 6,000,000 American Depositary Shares (ADSs), representing 6,000,000 Ascendis ordinary shares, at a price to the public of $18.00 per ADS. The ADSs are expected to begin trading on The NASDAQ Global Select Market on January 28, 2015 under the ticker symbol "ASND." All of the ADSs are being offered by Ascendis. Ascendis expects to close its initial public offering on or about February 2, 2015, subject to satisfaction of customary closing conditions. In addition, Ascendis has granted the underwriters a 30-day option to purchase up to an additional 900,000 ADSs. Ascendis estimates net proceeds from the offering to be approximately $96.4 million (assuming no exercise of the underwriters' option to purchase additional ADSs), after deducting underwriting commissions and estimated offering expenses.
BofA Merrill Lynch and Leerink Partners are acting as joint book-running managers for the offering. Wells Fargo Securities is acting as co-manager.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on January 27, 2015. Copies of the registration statement, as amended, can be accessed through the SEC's website at www.sec.gov.
This offering is being made solely by means of a prospectus, copies of which may be obtained by contacting BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or by email at dg.Prospectus_Requests@baml.com; or Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by email at syndicate@leerink.com, or by phone at (800) 808-7525.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.
Contact:
Investor Contact:
Martin Auster, M.D.
Chief Business Officer
+1 (650) 617-3403
ir@ascendispharma.com
Media Contact:
Marion Janic
Rooney & Associates
+1 (212) 223-4017
mjanic@rooneyco.com
Logo - http://photos.prnewswire.com/prnh/20150128/171828LOGO
Share this article